GGrantIndex
Sort

85,873 grants matching alzheimers

Peripheral Tissue Biomarker for Premortem Diagnosis of Lewy Body Dementia

$1,090,231
Shu G Chen · University Of Alabama At Birmingham · R01 · FY2025 · NS

Neurobiology of Mild Cognitive Impairment

$1,090,150
Elliott Jay Mufson · St. Joseph'S Hospital And Medical Center · P01 · FY2014 · AG

Development of Cdk5 Inhibitors

$1,090,050
Kenneth S Kosik · University Of California Santa Barbara · U01 · FY2009 · AG

Shared resource to develop tools and reagents to study structural polymorphisms in Abeta amyloid aggregates in AD

$1,089,558
Charles G Glabe · University Of California-Irvine · U24 · FY2023 · AG

Prediction of Psychosis in Alzheimer Disease

$1,089,531
Robert A Sweet · University Of Pittsburgh At Pittsburgh · R01 · FY2019 · AG

A Haplotype Map for Multiple Sclerosis

$1,089,455
Stephen L Hauser · University Of California, San Francisco · R01 · FY2010 · NS

Developing an Elderly Patient-Specific, Accurate, Intuitive and Highly Interpretable System for Unconsciousness Management in General Anesthesia Using PASCALL FDA-Cleared Intraoperative EEG Monitor

$1,089,346
Tuan Le Mau · Pascall Systems, Incorporated · R44 · FY2025 · AG

Shared resource to develop tools and reagents to study structural polymorphisms in Abeta amyloid aggregates in AD

$1,089,279
Charles G Glabe · University Of California-Irvine · U24 · FY2024 · AG

Shared resource to develop tools and reagents to study structural polymorphisms in Abeta amyloid aggregates in AD

$1,089,279
Charles G Glabe · University Of California-Irvine · U24 · FY2025 · AG

The Arabidopsis Transcription Factor ORFeome and downstream genomic application

$1,089,150
Steve A Kay · University Of California, San Diego · RC2 · FY2009 · GM

Neurostimulation and Recording of Real World Spatial Navigation in Humans

$1,089,050
Nanthia A Suthana · University Of California Los Angeles · U01 · FY2020 · NS

Phase 2 Enabling Studies of a Candidate Drug Therapy (T3D-959) Regulating Neurometabolism for the Treatment of Huntington's Disease

$1,088,768
John Didsbury · T3d Therapeutics, Inc. · R44 · FY2022 · NS

BIOLOGY OF ALZHEIMERS DISEASE IN TRANSGENIC MICE

$1,087,686
University Of Minnesota Twin Cities · P01 · FY2001 · AG

Dysfunctional lipid metabolism and peroxidation in chronic pain and neurodegeneration

$1,087,313
Christopher Ramsden · National Institute On Aging · ZIA · FY2019 · AG

Administrative Core

$1,087,048
Helena Chang Chui · University Of Southern California · P30 · FY2025 · AG

Alzheimer's Disease Patient Registry (ADPR)

$1,086,625
Group Health Cooperative · U01 · FY2004 · AG

Proof-of-Concept Trial of an Alpha-7 Nicotinic Agonist for Nicotine Dependence

$1,086,478
A Eden Evins · Massachusetts General Hospital · R01 · FY2015 · DA

Role of Neurotrophins and Their Receptors in the Development of the Mammalian Ne

$1,086,465
Lino Tessarollo · Basic Sciences · Z01 · FY2007 · CA

ALZHEIMERS RESEARCH PROJECT: Developing Extraceullar Vesicle biomarkers for clinical and preclinical AD/ADRD

$1,086,297
Dimitrios Kapogiannis · National Institute On Aging · ZIA · FY2025 · AG

ALZHEIMERS RESEARCH PROJECT / CLINICAL PROJECT: Mechanistic and clinical studies in Alzheimer's disease and related disorders

$1,086,297
Dimitrios Kapogiannis · National Institute On Aging · ZIA · FY2025 · AG

Tracking longitudinal change in presymptomatic genetic prion disease (TLC-Pre-gPrD)

$1,086,202
Michael D Geschwind · University Of California, San Francisco · R01 · FY2023 · AG

Novel Early Retinal Imaging Biomarkers for Treating Later Spatial Memory Loss in Experimental Alzheimer's Disease

$1,086,200
Bruce A. Berkowitz · Wayne State University · R01 · FY2024 · AG

Develop GABAergic Neuron Protectors for Treating ApoE4-Related Alzheimer's Disease

$1,086,082
Robert W. Mahley · Gabaeron, Inc. · R44 · FY2021 · AG

Development of cell free messenger RNA-based non-invasive diagnostic biomarker for Alzheimer's Disease

$1,086,079
John Joseph Sninsky · Superfluid Dx, Inc. · R44 · FY2023 · AG

Clinical Core

$1,086,072
Robert A Sweet · University Of Pittsburgh At Pittsburgh · P30 · FY2023 · AG